Latest Regulatory News

Trinex Minerals Limited has announced a significant 127:1 security consolidation affecting its ordinary shares, options, and performance rights, pending shareholder approval and set to reshape its capital structure by mid-July.

Immutep’s novel immunotherapy combination with radiotherapy and KEYTRUDA® has met its primary endpoint in a Phase II trial for resectable soft tissue sarcoma, showing promising early signs of improved patient outcomes.

Cash Converters has announced its exit from the Small Amount Credit Contract payday lending sector, signaling a strategic shift away from this controversial market segment.

Vault Minerals has expanded its King of the Hills open pit Ore Reserve by 33%, underpinning an 18-year mine life and announcing a $92 million Stage 2 plant upgrade to increase processing capacity to 7.5 million tonnes per annum.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.

Turners Automotive Group has reported a record FY25 performance, with net profit after tax rising 17% to $38.6 million and dividends increasing 14% to 29.0 cents per share, showcasing resilience amid challenging economic conditions.

Yowie Group has lodged a formal application with the Takeovers Panel to block Keybridge Capital from convening a shareholder meeting aimed at replacing Yowie’s board, accusing Keybridge of trying to frustrate its takeover offer.

Pioneer Lithium has completed the second tranche of its capital raising, issuing 1.6 million shares to directors following shareholder approval. This move strengthens the company’s capital base as it advances its lithium exploration ambitions.

Chorus Limited has lodged a replacement Product Disclosure Statement for its $170 million Capital Notes offer, confirming S&P’s equity content treatment and updating key offer dates and terms.

Reef Casino Trust reported stable 2024 financial results with steady distributions, while confidential takeover proposals from two groups are under board review. Operational challenges include rising regulatory costs and inflationary pressures.

Reef Casino Trust projects a drop in first-half distributable profit for 2025, citing stable revenues but increased regulatory and transaction-related expenses.

Neuren Pharmaceuticals has approved a significant long-term equity incentive plan tied to critical clinical and regulatory milestones for its drug candidate NNZ-2591, reinforcing management’s commitment to shareholder value.